Cantor Fitzgerald Reaffirms Neutral Rating for Regeneron Pharmaceuticals (NASDAQ:REGN)

Cantor Fitzgerald reiterated their neutral rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a report issued on Monday morning, Benzinga reports. They currently have a $1,015.00 target price on the biopharmaceutical company’s stock.

Several other research firms also recently issued reports on REGN. Royal Bank of Canada reissued an outperform rating and issued a $1,250.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, September 5th. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a strong-buy rating to a buy rating in a report on Monday, September 2nd. Wells Fargo & Company lifted their price objective on shares of Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the company an overweight rating in a research note on Friday, August 2nd. Barclays upped their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an overweight rating in a report on Friday, August 2nd. Finally, Evercore ISI initiated coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, May 14th. They set an outperform rating and a $1,150.00 target price for the company. One investment analyst has rated the stock with a sell rating, three have given a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $1,109.70.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $1,141.45 on Monday. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals has a 12 month low of $769.19 and a 12 month high of $1,211.20. The stock’s fifty day moving average price is $1,119.03 and its 200-day moving average price is $1,023.84. The firm has a market cap of $125.77 billion, a P/E ratio of 33.72, a P/E/G ratio of 3.86 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same period in the previous year, the company earned $8.79 earnings per share. On average, equities research analysts expect that Regeneron Pharmaceuticals will post 37.8 earnings per share for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,535 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $1,040.00, for a total transaction of $1,596,400.00. Following the completion of the sale, the director now directly owns 1,382 shares in the company, valued at approximately $1,437,280. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the transaction, the vice president now directly owns 4,204 shares in the company, valued at $4,498,280. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Michael S. Brown sold 1,535 shares of the stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $1,040.00, for a total transaction of $1,596,400.00. Following the completion of the sale, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,437,280. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,561 shares of company stock valued at $13,095,105. 7.48% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in REGN. West Paces Advisors Inc. increased its stake in shares of Regeneron Pharmaceuticals by 575.0% in the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 23 shares during the last quarter. Stephens Consulting LLC purchased a new position in Regeneron Pharmaceuticals during the second quarter worth about $26,000. Sachetta LLC boosted its holdings in Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares during the last quarter. Crewe Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at approximately $28,000. Finally, Lynx Investment Advisory acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $33,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.